X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15381) 15381
Book Review (4670) 4670
Publication (1118) 1118
Newsletter (170) 170
Book / eBook (157) 157
Conference Proceeding (41) 41
Newspaper Article (28) 28
Magazine Article (27) 27
Book Chapter (24) 24
Transcript (18) 18
Dissertation (3) 3
Presentation (2) 2
Report (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14605) 14605
humans (14356) 14356
female (8929) 8929
oncology (7367) 7367
middle aged (5955) 5955
male (5566) 5566
aged (5210) 5210
breast neoplasms - drug therapy (5011) 5011
cancer (4696) 4696
adult (4174) 4174
breast cancer (3972) 3972
chemotherapy (3953) 3953
antineoplastic agents, hormonal - therapeutic use (3660) 3660
treatment outcome (3534) 3534
antineoplastic combined chemotherapy protocols - therapeutic use (3411) 3411
antineoplastic agents - therapeutic use (3207) 3207
antineoplastic agents, hormonal - administration & dosage (2787) 2787
care and treatment (2783) 2783
breast neoplasms - pathology (2520) 2520
animals (2476) 2476
prostatic neoplasms - drug therapy (2366) 2366
medicine & public health (2051) 2051
aged, 80 and over (1970) 1970
therapy (1969) 1969
prostate cancer (1943) 1943
tamoxifen (1825) 1825
pharmacology & pharmacy (1805) 1805
research (1798) 1798
antineoplastic agents (1692) 1692
antineoplastic agents - administration & dosage (1629) 1629
drug therapy (1629) 1629
health aspects (1553) 1553
chemotherapy, adjuvant (1551) 1551
antineoplastic agents, hormonal - adverse effects (1504) 1504
antineoplastic agents - adverse effects (1479) 1479
metastasis (1419) 1419
prognosis (1406) 1406
drug administration schedule (1389) 1389
disease-free survival (1386) 1386
antimitotic agents (1344) 1344
neoplasm staging (1293) 1293
analysis (1278) 1278
carcinoma (1263) 1263
antineoplastic combined chemotherapy protocols - adverse effects (1251) 1251
abridged index medicus (1184) 1184
tamoxifen - therapeutic use (1160) 1160
antineoplastic agents - pharmacology (1132) 1132
urology & nephrology (1128) 1128
tumors (1120) 1120
neoplasm metastasis (1105) 1105
prostatic neoplasms - pathology (1105) 1105
combined modality therapy (1099) 1099
hematology, oncology and palliative medicine (1088) 1088
retrospective studies (1076) 1076
survival analysis (1074) 1074
postmenopausal women (1066) 1066
tamoxifen - administration & dosage (1065) 1065
neoplasms - drug therapy (1054) 1054
survival (1049) 1049
risk factors (1045) 1045
clinical trials (1041) 1041
dose-response relationship, drug (1025) 1025
docetaxel (1017) 1017
women (1012) 1012
time factors (1010) 1010
breast neoplasms - metabolism (1004) 1004
follow-up studies (986) 986
clinical trials as topic (936) 936
antineoplastic agents, hormonal - pharmacology (927) 927
breast neoplasms - mortality (914) 914
trial (900) 900
mice (892) 892
antineoplastic combined chemotherapy protocols - administration & dosage (869) 869
survival rate (854) 854
obstetrics & gynecology (850) 850
expression (821) 821
breast-cancer (813) 813
estrogen (808) 808
prospective studies (772) 772
dosage and administration (753) 753
radiotherapy (752) 752
disease progression (751) 751
drug resistance, neoplasm (748) 748
cell line, tumor (746) 746
surgery (726) 726
randomized controlled trials as topic (720) 720
cancer therapies (711) 711
breast neoplasms - surgery (705) 705
endocrine therapy (705) 705
endocrinology & metabolism (703) 703
apoptosis (701) 701
article (701) 701
quality of life (698) 698
oncology, experimental (695) 695
trastuzumab (695) 695
prostate-specific antigen - blood (690) 690
androgen antagonists - therapeutic use (689) 689
randomized-trial (687) 687
cyclophosphamide - administration & dosage (685) 685
phase-ii trial (684) 684
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (122) 122
Collection Dvlpm't (Acquisitions) - Closed Orders (9) 9
Collection Dvlpm't (Acquisitions) - Vendor file (9) 9
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Online Resources - Online (3) 3
Chemistry (A D Allen) - Stacks (2) 2
Credit Valley Hospital - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Scarborough Hospital - Birchmount (1) 1
St. Michael's Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15113) 15113
Japanese (226) 226
German (108) 108
French (92) 92
Russian (66) 66
Italian (41) 41
Spanish (36) 36
Chinese (29) 29
Hungarian (23) 23
Polish (16) 16
Danish (9) 9
Portuguese (6) 6
Czech (5) 5
Norwegian (5) 5
Swedish (5) 5
Dutch (4) 4
Romanian (3) 3
Bulgarian (2) 2
Finnish (2) 2
Serbian (2) 2
Ukrainian (2) 2
Croatian (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10024, pp. 1163 - 1177
Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled... 
Internal Medicine | ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | PREDNISONE | DESIGN | MITOXANTRONE | CABAZITAXEL | CLINICAL-TRIALS | OPEN-LABEL | CHEMOTHERAPY | ENZALUTAMIDE | ESTRAMUSTINE | Survival analysis | Medical prognosis | Clinical trials | Hormone replacement therapy | Metastasis | Prostate cancer | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 8, pp. 766 - 776
This study of adjuvant hormonal therapy in postmenopausal women with hormone-receptor–positive early breast cancer showed that disease-free survival was... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | EXEMESTANE | CONTINUED TAMOXIFEN | ADJUVANT ENDOCRINE THERAPY | RANDOMIZED-TRIAL | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | ANASTROZOLE | Aromatase Inhibitors - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Neoplasm Recurrence, Local - prevention & control | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Kaplan-Meier Estimate | Proportional Hazards Models | Fractures, Bone - epidemiology | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Incidence | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Postmenopause | Female | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Nitriles - adverse effects | Women | Care and treatment | Usage | Breast cancer | Tamoxifen | Comparative analysis | Health aspects | Drug therapy | Womens health | Cancer therapies | Index Medicus | Abridged Index Medicus | Hormonal | Breast Neoplasms | epidemiology | administration & dosage | Triazoles | Nitriles | Adjuvant | drug therapy | Antineoplastic Agents | Local | prevention & control | Aromatase Inhibitors | Chemotherapy | Fractures | adverse effects | Bone | Neoplasm Recurrence | Cancer and Oncology | Kaplan-Meiers Estimate | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3742 - 3748
Purpose It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent. Abiraterone acetate is a potent, selective,... 
LEUKEMIA GROUP-B | II CLINICAL-TRIALS | WORKING GROUP | ANTIANDROGEN WITHDRAWAL | ANDROGEN BIOSYNTHESIS | ONCOLOGY | STEROIDAL INHIBITORS | PHASE-II | END-POINTS | DOSE KETOCONAZOLE | HORMONAL-THERAPY | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prospective Studies | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Neoplasms, Hormone-Dependent - immunology | Androstenols - therapeutic use | Prostatic Neoplasms - immunology | Enzyme Inhibitors - administration & dosage | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Testosterone - blood | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Antineoplastic Agents, Hormonal - pharmacology | Drug Administration Schedule | Androstenols - pharmacology | Antineoplastic Agents, Hormonal - administration & dosage | Enzyme Inhibitors - pharmacology | Kaplan-Meier Estimate | Androgen Antagonists - pharmacology | Androstenes | Enzyme Inhibitors - therapeutic use | Disease Progression | Prostate-Specific Antigen - blood | Neoplasms, Hormone-Dependent - pathology | Androgen Antagonists - therapeutic use | Aged | Androstenols - administration & dosage | Androgen Antagonists - administration & dosage | Neoplasms, Hormone-Dependent - drug therapy | Adrenal Cortex Hormones - administration & dosage | Index Medicus
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 09/2014, Volume 472, Issue 1-2, pp. 20 - 26
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
EFFICACY | ONCOLOGY | RANDOMIZED PHASE-II | TAMOXIFEN RESISTANCE | GROWTH | MCF-7 CELLS | COMBINATION | INHIBITOR | EXPRESSION | ESTROGEN-RECEPTOR | PLUS | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 06/2016, Volume 22, Issue 11, pp. 2650 - 2658
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 14, pp. 1314 - 1325
Despite theoretical benefits of intermittent as compared with continuous androgen-deprivation therapy in patients with metastatic prostate cancer, intermittent... 
MEDICINE, GENERAL & INTERNAL | THERAPY | CLINICAL-TRIAL | FLUTAMIDE | QUALITY-OF-LIFE | SUPPRESSION | CARCINOMA | LEUPROLIDE | Confidence Intervals | Follow-Up Studies | Anilides - adverse effects | Humans | Middle Aged | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis - drug therapy | Penile Erection - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Goserelin - adverse effects | Prostatic Neoplasms - drug therapy | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Tosyl Compounds - adverse effects | Anilides - administration & dosage | Survival Analysis | Quality of Life | Aged | Androgen Antagonists - administration & dosage | Nitriles - adverse effects | Usage | Care and treatment | Patient outcomes | Androgen suppression therapy | Drug therapy | Prostate cancer | Methods | Cancer | Statistical analysis | Mental disorders | Prostate-specific antigen | Clinical trials | Patients | Survival | Quality of life | Metastases | Androgens | Castration | Stem cells | Luteinizing hormone | Prostate | Index Medicus | Abridged Index Medicus
Journal Article
9.